nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—HTR6—forebrain—attention deficit hyperactivity disorder	0.0217	0.0771	CbGeAlD
Raloxifene—ESR2—forebrain—attention deficit hyperactivity disorder	0.0152	0.0542	CbGeAlD
Raloxifene—ESR2—cardiovascular system—attention deficit hyperactivity disorder	0.0129	0.0458	CbGeAlD
Raloxifene—CYP19A1—forebrain—attention deficit hyperactivity disorder	0.012	0.0427	CbGeAlD
Raloxifene—HTR6—nervous system—attention deficit hyperactivity disorder	0.0118	0.0419	CbGeAlD
Raloxifene—HTR2B—forebrain—attention deficit hyperactivity disorder	0.0118	0.0419	CbGeAlD
Raloxifene—HTR6—central nervous system—attention deficit hyperactivity disorder	0.0113	0.0403	CbGeAlD
Raloxifene—ESR1—forebrain—attention deficit hyperactivity disorder	0.0104	0.0371	CbGeAlD
Raloxifene—HTR2B—cardiovascular system—attention deficit hyperactivity disorder	0.00996	0.0354	CbGeAlD
Raloxifene—HTR6—brain—attention deficit hyperactivity disorder	0.009	0.032	CbGeAlD
Raloxifene—ESR1—cardiovascular system—attention deficit hyperactivity disorder	0.00882	0.0314	CbGeAlD
Raloxifene—ESR2—nervous system—attention deficit hyperactivity disorder	0.00827	0.0294	CbGeAlD
Raloxifene—ESR2—central nervous system—attention deficit hyperactivity disorder	0.00796	0.0283	CbGeAlD
Raloxifene—SIGMAR1—midbrain—attention deficit hyperactivity disorder	0.00779	0.0277	CbGeAlD
Raloxifene—ESR2—cerebellum—attention deficit hyperactivity disorder	0.00778	0.0277	CbGeAlD
Raloxifene—AOX1—cerebellum—attention deficit hyperactivity disorder	0.00749	0.0266	CbGeAlD
Raloxifene—CYP2B6—cardiovascular system—attention deficit hyperactivity disorder	0.00652	0.0232	CbGeAlD
Raloxifene—CYP19A1—nervous system—attention deficit hyperactivity disorder	0.00652	0.0232	CbGeAlD
Raloxifene—HTR2B—nervous system—attention deficit hyperactivity disorder	0.00639	0.0227	CbGeAlD
Raloxifene—ESR2—brain—attention deficit hyperactivity disorder	0.00632	0.0225	CbGeAlD
Raloxifene—CYP19A1—central nervous system—attention deficit hyperactivity disorder	0.00627	0.0223	CbGeAlD
Raloxifene—HTR2B—central nervous system—attention deficit hyperactivity disorder	0.00615	0.0219	CbGeAlD
Raloxifene—AOX1—brain—attention deficit hyperactivity disorder	0.00608	0.0216	CbGeAlD
Raloxifene—SIGMAR1—cerebellum—attention deficit hyperactivity disorder	0.00603	0.0214	CbGeAlD
Raloxifene—ESR1—nervous system—attention deficit hyperactivity disorder	0.00566	0.0201	CbGeAlD
Raloxifene—ESR1—central nervous system—attention deficit hyperactivity disorder	0.00545	0.0194	CbGeAlD
Raloxifene—ESR1—cerebellum—attention deficit hyperactivity disorder	0.00533	0.019	CbGeAlD
Raloxifene—CYP19A1—brain—attention deficit hyperactivity disorder	0.00498	0.0177	CbGeAlD
Raloxifene—SIGMAR1—brain—attention deficit hyperactivity disorder	0.0049	0.0174	CbGeAlD
Raloxifene—HTR2B—brain—attention deficit hyperactivity disorder	0.00489	0.0174	CbGeAlD
Raloxifene—ESR1—brain—attention deficit hyperactivity disorder	0.00433	0.0154	CbGeAlD
Raloxifene—CYP2B6—nervous system—attention deficit hyperactivity disorder	0.00418	0.0149	CbGeAlD
Raloxifene—CYP2B6—central nervous system—attention deficit hyperactivity disorder	0.00403	0.0143	CbGeAlD
Raloxifene—CYP2C8—brain—attention deficit hyperactivity disorder	0.00357	0.0127	CbGeAlD
Raloxifene—CYP2B6—brain—attention deficit hyperactivity disorder	0.0032	0.0114	CbGeAlD
Raloxifene—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00316	0.0112	CbGeAlD
Raloxifene—ESR2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00313	0.00436	CbGpPWpGaD
Raloxifene—CYP19A1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00307	0.00427	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00305	0.00425	CbGpPWpGaD
Raloxifene—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00304	0.0108	CbGeAlD
Raloxifene—ESR2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00302	0.0042	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00299	0.00416	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00297	0.00413	CbGpPWpGaD
Raloxifene—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00292	0.00406	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00287	0.00399	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00281	0.00391	CbGpPWpGaD
Raloxifene—ESR2—Validated nuclear estrogen receptor alpha network—EP300—attention deficit hyperactivity disorder	0.00276	0.00384	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00262	0.00364	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00257	0.00358	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00256	0.00356	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00255	0.00355	CbGpPWpGaD
Raloxifene—EBP—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00235	0.00326	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00227	0.00316	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00218	0.00304	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00214	0.00297	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00207	0.00288	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00199	0.00277	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00199	0.00276	CbGpPWpGaD
Raloxifene—CYP2B6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00197	0.00274	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00195	0.00271	CbGpPWpGaD
Raloxifene—ESR1—FOXM1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00195	0.00271	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00195	0.00271	CbGpPWpGaD
Raloxifene—ESR1—FOXA1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00188	0.00261	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00185	0.00257	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00184	0.00256	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00181	0.00252	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00181	0.00252	CbGpPWpGaD
Raloxifene—AOX1—Disease—STUB1—attention deficit hyperactivity disorder	0.00181	0.00251	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00179	0.00249	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00178	0.00247	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00176	0.00244	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00174	0.00241	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.0017	0.00237	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00168	0.00234	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00168	0.00233	CbGpPWpGaD
Raloxifene—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00167	0.00232	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00167	0.00232	CbGpPWpGaD
Raloxifene—CYP19A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00164	0.00229	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00163	0.00227	CbGpPWpGaD
Raloxifene—CYP19A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00163	0.00227	CbGpPWpGaD
Raloxifene—CYP19A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00162	0.00225	CbGpPWpGaD
Raloxifene—EBP—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00162	0.00225	CbGpPWpGaD
Raloxifene—EBP—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00162	0.00225	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00162	0.00225	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.0016	0.00223	CbGpPWpGaD
Raloxifene—EBP—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00159	0.00222	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00158	0.0022	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00158	0.0022	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00155	0.00216	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00153	0.00213	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00152	0.00212	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00151	0.00209	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00149	0.00207	CbGpPWpGaD
Raloxifene—ESR1—ATF-2 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00148	0.00207	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00148	0.00206	CbGpPWpGaD
Raloxifene—EBP—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00148	0.00206	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00148	0.00205	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00144	0.00201	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.0014	0.00194	CbGpPWpGaD
Raloxifene—ESR1—Validated nuclear estrogen receptor alpha network—EP300—attention deficit hyperactivity disorder	0.00139	0.00194	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00139	0.00193	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00137	0.00191	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00136	0.00189	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—POLR3A—attention deficit hyperactivity disorder	0.00135	0.00188	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00135	0.00188	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00135	0.00188	CbGpPWpGaD
Raloxifene—HTR2B—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00134	0.00186	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.0013	0.00181	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.0013	0.0018	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.0013	0.0018	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.0013	0.0018	CbGpPWpGaD
Raloxifene—EBP—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00129	0.0018	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00126	0.00176	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00123	0.00172	CbGpPWpGaD
Raloxifene—EBP—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00123	0.00171	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00121	0.00168	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.0012	0.00168	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.0012	0.00166	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00118	0.00164	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00117	0.00162	CbGpPWpGaD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—EP300—attention deficit hyperactivity disorder	0.00115	0.0016	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00115	0.0016	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00115	0.00159	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00113	0.00158	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00113	0.00157	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00113	0.00157	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.00156	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.0011	0.00153	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.0011	0.00153	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.0011	0.00153	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00106	0.00148	CbGpPWpGaD
Raloxifene—CYP2B6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00106	0.00147	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00105	0.00147	CbGpPWpGaD
Raloxifene—CYP2B6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00105	0.00146	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00105	0.00146	CbGpPWpGaD
Raloxifene—CYP2B6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00104	0.00145	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00103	0.00144	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00103	0.00144	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00102	0.00142	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.001	0.00139	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000986	0.00137	CbGpPWpGaD
Raloxifene—EBP—Metabolism—COMT—attention deficit hyperactivity disorder	0.000981	0.00136	CbGpPWpGaD
Raloxifene—EBP—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000974	0.00135	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00097	0.00135	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000963	0.00134	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000944	0.00131	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.0009	0.00125	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000897	0.00125	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000897	0.00125	CbGpPWpGaD
Raloxifene—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000896	0.00125	CbGpPWpGaD
Raloxifene—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000893	0.00124	CbGpPWpGaD
Raloxifene—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000887	0.00123	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000885	0.00123	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000882	0.00123	CbGpPWpGaD
Raloxifene—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000881	0.00123	CbGpPWpGaD
Raloxifene—AOX1—Disease—SNAP25—attention deficit hyperactivity disorder	0.000856	0.00119	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000837	0.00116	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00082	0.00114	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000782	0.00109	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00077	0.00107	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000764	0.00106	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00076	0.00106	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00075	0.00104	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000739	0.00103	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000732	0.00102	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000717	0.000997	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000703	0.000978	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.0007	0.000974	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000694	0.000966	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000683	0.00095	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—POLR3A—attention deficit hyperactivity disorder	0.000682	0.000949	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000681	0.000947	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000674	0.000938	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000672	0.000935	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000668	0.000929	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000665	0.000925	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000662	0.00092	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000659	0.000917	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000648	0.000902	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000648	0.000901	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00064	0.00089	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000636	0.000884	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000621	0.000864	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000618	0.00086	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000607	0.000844	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000604	0.00084	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000602	0.000837	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000599	0.000833	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000596	0.000829	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000592	0.000823	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000591	0.000823	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000588	0.000818	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000586	0.000814	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000584	0.000812	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000581	0.000808	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00058	0.000807	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00058	0.000807	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000564	0.000785	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000546	0.00076	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000544	0.000757	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000543	0.000756	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000541	0.000753	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00054	0.000751	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000537	0.000747	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00053	0.000738	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000503	0.0007	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000494	0.000687	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000493	0.000686	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000483	0.000672	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00048	0.000667	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000476	0.000662	CbGpPWpGaD
Raloxifene—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000473	0.000658	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000464	0.000645	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000464	0.000645	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000456	0.000635	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000449	0.000625	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000432	0.0006	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000424	0.00059	CbGpPWpGaD
Raloxifene—EBP—Metabolism—EP300—attention deficit hyperactivity disorder	0.000421	0.000585	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000417	0.000581	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00041	0.00057	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000393	0.000546	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000381	0.00053	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000379	0.000527	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000371	0.000516	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000365	0.000508	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000365	0.000508	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000358	0.000499	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000354	0.000492	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000353	0.000491	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000348	0.000483	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000346	0.000481	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000343	0.000477	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000342	0.000475	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000333	0.000464	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000323	0.000449	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00032	0.000445	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000317	0.000441	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000313	0.000436	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000299	0.000415	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000298	0.000414	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000298	0.000414	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000293	0.000408	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000292	0.000406	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000281	0.000391	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000279	0.000388	CbGpPWpGaD
Raloxifene—AOX1—Disease—EP300—attention deficit hyperactivity disorder	0.000278	0.000387	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000278	0.000386	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000272	0.000379	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000271	0.000376	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000269	0.000374	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000264	0.000368	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000261	0.000363	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000252	0.000351	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000252	0.000351	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000248	0.000345	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000243	0.000338	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000238	0.000331	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000233	0.000324	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000231	0.000321	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000227	0.000315	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000224	0.000312	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000204	0.000284	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000202	0.00028	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000196	0.000273	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000192	0.000267	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—COMT—attention deficit hyperactivity disorder	0.00018	0.000251	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000179	0.000249	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00017	0.000237	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	0.000153	0.000213	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000152	0.000211	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000147	0.000205	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000135	0.000188	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000135	0.000188	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000133	0.000185	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000124	0.000172	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000121	0.000168	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000119	0.000165	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000108	0.000151	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000108	0.000151	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000103	0.000143	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.02e-05	0.000125	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	8.2e-05	0.000114	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	8.14e-05	0.000113	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—EP300—attention deficit hyperactivity disorder	7.74e-05	0.000108	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	6.55e-05	9.11e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.52e-05	4.89e-05	CbGpPWpGaD
